# OnCo record tmb-testing (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/tmb-testing/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "tmb-testing" ;
  schema:name "Tumour mutational burden testing"@en ;
  schema:description "Counting how many mutations a tumour carries per stretch of DNA; heavily mutated tumours are more likely to respond to immunotherapy."@en ;
  schema:url <https://onco.cc/technologies/tmb-testing/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors> ;
  onco:status "established" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/foundationone-cdx/>, <https://onco.cc/drugs/trusight-oncology-comprehensive/> ;
  onco:terms <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/msi/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018/>, <https://onco.cc/key-papers/paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022/>, <https://onco.cc/key-papers/paper-keynote-189-407-tmb-jtocrr-2023/>, <https://onco.cc/key-papers/paper-gandara-blood-tmb-atezolizumab-nat-med-2018/> .